Can Iron Infusion Cause Elevated Liver Enzymes?

Iron infusions can cause elevated liver enzymes, and the effect is well-documented in clinical practice. In a study of patients with inflammatory bowel disease receiving ferric carboxymaltose, a transient rise in liver enzymes was the single most common adverse event reported. The elevations are usually temporary and mild, but several factors, including the specific iron formulation used, your sex, and whether you have pre-existing liver disease, influence how likely you are to experience them and how much they matter.

Why Iron Can Stress the Liver

The liver is the body’s main storage site for iron, which makes it the first organ to feel the effects when a large dose of iron enters the bloodstream all at once. Under normal circumstances, iron is tightly regulated by proteins that shuttle it safely into storage. When an intravenous infusion delivers a concentrated load, some of that iron can temporarily exceed the body’s binding capacity, leaving “free” iron circulating in the blood.

Free iron is chemically reactive. It serves as a raw ingredient for the production of reactive oxygen species, unstable molecules that damage cell membranes, proteins, and DNA. In the liver, this oxidative stress can injure hepatocytes, the cells that do most of the liver’s metabolic work. A related process called ferroptosis, an iron-dependent form of cell death, has been gaining attention as a driver of liver damage in iron-overloaded states.¹ When hepatocytes are injured or die, they release enzymes like ALT and AST into the blood. A routine blood test picks up these elevated levels, and your doctor flags them as “elevated liver enzymes.”

This does not mean that every iron infusion will produce noticeable liver stress. In many people, the body’s antioxidant defenses mop up the reactive iron quickly enough that no measurable enzyme rise occurs. But the mechanism is always at play to some degree, which is why monitoring liver function is standard practice around IV iron therapy.

How Common Are Liver Enzyme Elevations After Iron Infusions

The best human data on frequency comes from a study of 232 patients with inflammatory bowel disease who received ferric carboxymaltose, one of the most commonly prescribed IV iron products. A transient increase in liver enzymes was the most frequently reported side effect. Male patients were significantly more likely to develop this reaction, with roughly eight and a half times the odds compared to female patients.² The word “transient” is key here: in most cases, enzyme levels drifted back toward normal without any specific intervention, and the elevations were not associated with lasting liver damage.

Data from patients receiving repeated blood transfusions (a different route of iron loading, but one that produces similar iron accumulation in the liver) paints a complementary picture. Among 39 adults with acquired anemias who had built up excess iron from transfusions, over half had elevated ALT levels and about a quarter had elevated AST levels. The elevations tracked with the amount of iron stored in the liver: aminotransferase levels stayed normal when liver iron was below a certain concentration, and they climbed once iron stores passed a threshold.³ This suggests a dose-dependent relationship: a single infusion is far less likely to produce the iron concentrations at which enzymes start rising than months or years of repeated transfusions.

The Formulation You Receive Matters More Than You Might Think

Not all IV iron products behave the same way in the body, and this has real consequences for liver safety. A head-to-head animal study compared the original ferric carboxymaltose product to a newer “similar” version (sometimes called a generic or follow-on product). The results were striking: the similar product caused substantially and significantly higher AST, ALT, and alkaline phosphatase levels compared to both the originator product and a saline control. The liver enzyme increases appeared as early as the first day after infusion and did not diminish over the study period.⁴

Meanwhile, the originator ferric carboxymaltose group showed liver enzyme levels that remained similar to the control group throughout. The researchers attributed the difference to how each formulation releases iron. IV iron products wrap elemental iron inside a carbohydrate shell. How tightly that shell holds onto the iron, and how quickly it releases it once in the body, determines how much free iron floods the system at any given moment. A looser shell means more free iron, more oxidative stress, and more hepatocyte injury.

This finding has practical implications. If your doctor offers you an IV iron infusion, the specific brand or formulation is not an interchangeable detail. Regulatory agencies in some countries have begun treating IV iron products as non-interchangeable biologics precisely because manufacturing differences in the carbohydrate shell can alter safety profiles. If you have had liver enzyme elevations from a previous infusion, switching to a different formulation is a reasonable conversation to have with your prescriber.

Who Is at Higher Risk

Several groups face a greater chance of developing elevated liver enzymes after iron infusions, and the reasons differ by group.

Men: The IBD study identified male sex as an independent risk factor for transient liver enzyme elevation, with an odds ratio of about 8.6.² The reason is not entirely clear, but men tend to have higher baseline iron stores than premenopausal women, so an additional iron load may push them past the threshold where oxidative damage starts more quickly.
People with existing liver disease: If your liver is already inflamed or fibrotic, its capacity to handle an extra iron load safely is reduced. The liver remains the main target organ for iron deposition regardless of how the iron gets there, and any pre-existing damage narrows the margin between a tolerable dose and one that tips into measurable injury.⁵
Dialysis patients: People on hemodialysis receive IV iron frequently, sometimes over years. A study using MRI to measure liver iron found that dialysis patients with moderate or severe iron overload had significantly more liver fat than those with normal iron stores. Nearly all patients with heavy iron loading showed abnormal liver fat levels, compared to roughly half of those with normal stores.⁶ This is a concern that goes beyond enzyme bumps: chronic iron overload in these patients may be contributing to fatty liver disease itself.
Patients needing repeated infusions: A single infusion might produce a brief, harmless enzyme spike. But when infusions are repeated over months or years, as happens in chronic kidney disease, certain anemias, or heavy menstrual bleeding that keeps recurring, the cumulative iron load in the liver can cross into territory where sustained damage occurs.

A Transient Bump Versus a Real Problem

One of the most important distinctions your doctor will make after seeing elevated liver enzymes is whether the rise is a short-lived side effect or a sign of something more serious. A mild, transient enzyme elevation after an iron infusion, one that returns to normal within a few weeks without intervention, is generally not considered a reason to stop treatment. The benefits of correcting severe iron deficiency anemia usually outweigh the temporary liver stress.

A more worrying pattern is a persistent or progressive rise in enzymes, especially if it occurs alongside symptoms like jaundice, abdominal pain, or dark urine. In transfusional iron overload, enzyme elevations tracked reliably with the amount of iron concentrated in the liver: once liver iron dropped below a certain level during chelation therapy, enzyme values normalized in every case studied.³ This reversibility is reassuring: the liver enzyme elevation from iron is a direct reflection of iron-mediated damage, and removing the excess iron allows the liver to recover.

An animal model adds a counterintuitive piece to this puzzle. Researchers gave high-dose IV iron to rats that already had cirrhosis to see if the iron would make their liver damage worse. Even at the highest doses tested, the iron-treated cirrhotic rats did not show significantly higher AST or ALT levels compared to cirrhotic rats that received no iron at all.⁷ All the cirrhotic groups had dramatically elevated enzymes compared to healthy controls, but the iron infusion itself did not pile additional measurable damage on top of the existing cirrhosis. This is a single animal study, so its application to humans is limited, but it raises the possibility that the liver’s response to IV iron depends partly on the type and stage of any pre-existing disease.

What to Do If Your Enzymes Rise

If a blood test shows elevated liver enzymes after an iron infusion, the first step is usually to recheck them in two to four weeks. Most infusion-related elevations resolve on their own within that window. Your doctor will also want to rule out other causes, including medications, alcohol, viral hepatitis, or underlying fatty liver disease, since iron infusion is just one of many things that can nudge liver enzymes upward.

If enzymes stay elevated or climb higher, the conversation shifts. Your doctor may order imaging (like an ultrasound or MRI) to check for iron accumulation in the liver, adjust the timing or dose of future infusions, or consider switching to a different IV iron formulation. In extreme cases involving repeated iron loading over long periods, iron chelation therapy can be used to draw excess iron out of the liver. As the transfusional overload data showed, enzyme levels normalize reliably once excess iron is removed.

It is worth knowing that the conventional liver enzyme test, ALT, is not always the earliest or most sensitive indicator of iron-related liver injury. Research into newer biomarkers has shown that certain markers, such as keratin-18 fragments and microRNA-122, can rise earlier and to a greater degree than ALT during drug-induced liver injury.⁸ These biomarkers are not yet part of routine clinical practice for monitoring iron therapy, but they may become useful in the future for catching liver stress earlier, particularly in patients who require frequent infusions.

The Role of Oxidative Stress and Why Antioxidants Keep Coming Up

Because the mechanism connecting iron infusions to liver enzyme elevation runs through oxidative stress, researchers have been investigating whether antioxidant compounds can blunt the damage. Two recent animal studies offer preliminary hints.

One group found that theaflavins, a class of compounds found in black tea, counteracted iron overload-induced ferroptosis and the liver damage that followed in a lab model.⁹ A separate study tested an extract from beetroot and found that it reduced iron-mediated oxidative markers in rat liver tissue nearly back to normal levels at higher concentrations.¹⁰

To be clear, neither study was conducted in humans, and neither tested the compounds alongside IV iron infusions specifically. Drinking more black tea or eating more beets before your next infusion is not a proven liver-protection strategy. But the consistency of the finding, that bolstering the liver’s antioxidant defenses reduces iron-driven damage, supports the broader mechanistic picture and points toward where future clinical interventions might develop. For now, the best protective strategy is the less glamorous one: monitoring liver function, using well-characterized iron formulations, and spacing infusions appropriately to give the liver time to process each dose.

Chronic Iron Loading and Fatty Liver Disease

Beyond the acute enzyme-elevation question, a longer-term concern is whether repeated iron infusions contribute to fatty liver disease. The evidence in dialysis patients suggests this is a real phenomenon. Patients on hemodialysis who accumulated moderate or severe liver iron overload, as measured by MRI, had significantly higher liver fat content than those with normal iron stores. About 94% of the heavy-overload group had abnormally elevated liver fat, compared to roughly half of the group with normal iron.⁶

This association does not prove that iron caused the fat accumulation; dialysis patients have many overlapping metabolic risk factors. But the oxidative stress mechanism makes the connection biologically plausible. Iron-driven reactive oxygen species can trigger inflammation in the liver, and chronic low-grade inflammation is one of the pathways through which fatty liver disease develops and progresses. For people who need frequent iron infusions, periodic imaging to assess liver iron concentration, not just blood enzyme levels, may provide a more complete picture of what is happening inside the organ.

This is also a space where the evidence is evolving. Most of the studies establishing the link between iron loading and liver fat have been cross-sectional, meaning they captured a single snapshot in time rather than tracking changes as iron accumulated. Longitudinal studies following patients through years of IV iron therapy are relatively scarce, and the field could use more of them. If you are someone who receives iron infusions regularly, it is reasonable to ask your doctor whether liver iron monitoring (via MRI) is appropriate in your case, rather than relying solely on enzyme blood tests that may miss subtler forms of accumulation.